Arrowhead Pharmaceuticals, Inc. (ARWR)Healthcare | Biotechnology | Pasadena, United States | NasdaqGS
69.51 USD
+1.53
(2.251%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 70.49 +0.98 (1.410%) ⇧ (April 17, 2026, 7:35 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 8:02 p.m. EDT
Arrowhead Pharmaceuticals is currently in a classic momentum breakout phase, trading above its 50-day and 200-day moving averages with revenue growth exceeding 100%. Despite the 'proposed offering' news which often signals dilution fears, the market is aggressively ignoring it, focusing instead on the 'Moderate Buy' consensus and the potential 72% upside in intrinsic value. The options market confirms this conviction, with heavy calls stacked at $70 and above, signaling a high-probability attempt to test the $81 analyst target in the near term. The lack of a dividend is irrelevant for this growth play, making it a classic biotech momentum trade rather than a yield vehicle. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.078407 |
| MSTL | 0.081183 |
| AutoTheta | 0.259644 |
| AutoARIMA | 0.366967 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 57% |
| H-stat | 2.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.878 |
| Excess Kurtosis | -0.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 124.074 |
| Revenue per Share | 7.975 |
| Market Cap | 9,733,638,144 |
| Trailing P/E | 43.44 |
| Forward P/E | -16.18 |
| Beta | 1.27 |
| Profit Margins | 18.54% |
| Website | https://arrowheadpharma.com |
As of April 18, 2026, 8:02 p.m. EDT: Speculators are heavily positioning for upside, evidenced by significant call volume at the 70 strike (current price is 69.51) across near-term (April) and long-term (June/Sept) expirations, creating a substantial 'Call Wall' at current levels. While April puts show elevated OI near 62.5 and 65, indicating some protective hedging, the sheer volume of OTM calls (especially the 2.0k and 904 contracts at 80 and 90 strikes for Sept) suggests a 'gamma squeeze' potential if the stock clears the 70 resistance. The IV structure is steep in OTM puts, signaling fear of a drop below 60, but the dominant flow is bullish momentum seeking to push toward the 80-90 targets.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.754139 |
| Address1 | 177 East Colorado Boulevard |
| Address2 | Suite 700 |
| All Time High | 2,925.0 |
| All Time Low | 1.2 |
| Ask | 70.55 |
| Ask Size | 13 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,901,240 |
| Average Daily Volume3 Month | 2,678,633 |
| Average Volume | 2,678,633 |
| Average Volume10Days | 1,901,240 |
| Beta | 1.269 |
| Bid | 68.78 |
| Bid Size | 13 |
| Board Risk | 8 |
| Book Value | 4.137 |
| City | Pasadena |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 69.51 |
| Current Ratio | 3.38 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 70.89 |
| Day Low | 68.86 |
| Debt To Equity | 124.074 |
| Display Name | Arrowhead Pharmaceuticals |
| Earnings Call Timestamp End | 1,770,327,000 |
| Earnings Call Timestamp Start | 1,770,327,000 |
| Earnings Timestamp | 1,770,325,200 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | 325,649,984 |
| Ebitda Margins | 0.29849002 |
| Enterprise To Ebitda | 29.207 |
| Enterprise To Revenue | 8.718 |
| Enterprise Value | 9,511,365,632 |
| Eps Current Year | -3.23818 |
| Eps Forward | -4.296 |
| Eps Trailing Twelve Months | 1.6 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 626 304 3401 |
| Fifty Day Average | 61.9301 |
| Fifty Day Average Change | 7.5799026 |
| Fifty Day Average Change Percent | 0.12239449 |
| Fifty Two Week Change Percent | 475.41388 |
| Fifty Two Week High | 76.76 |
| Fifty Two Week High Change | -7.25 |
| Fifty Two Week High Change Percent | -0.094450235 |
| Fifty Two Week Low | 10.95 |
| Fifty Two Week Low Change | 58.56 |
| Fifty Two Week Low Change Percent | 5.347945 |
| Fifty Two Week Range | 10.95 - 76.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 756,052,200,000 |
| Float Shares | 122,039,454 |
| Forward Eps | -4.296 |
| Forward P E | -16.180168 |
| Free Cashflow | 170,725,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 711 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 1,090,980,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03797 |
| Held Percent Institutions | 0.84553003 |
| Implied Shares Outstanding | 140,032,190 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.arrowheadresearch.com/invest.html |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,321,488,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California. |
| Long Name | Arrowhead Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 9,733,638,144 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_203142 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 202,264,992 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 9,733,637,526 |
| Number Of Analyst Opinions | 11 |
| Open | 69.77 |
| Operating Cashflow | 339,304,992 |
| Operating Margins | 0.15456 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 626 304 3400 |
| Post Market Change | 0.9799957 |
| Post Market Change Percent | 1.4098629 |
| Post Market Price | 70.49 |
| Post Market Time | 1,776,468,953 |
| Previous Close | 67.98 |
| Price Eps Current Year | -21.465763 |
| Price Hint | 2 |
| Price To Book | 16.80203 |
| Price To Sales Trailing12 Months | 8.921913 |
| Profit Margins | 0.18540001 |
| Quick Ratio | 3.263 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 1.53 |
| Regular Market Change Percent | 2.25066 |
| Regular Market Day High | 70.89 |
| Regular Market Day Low | 68.86 |
| Regular Market Day Range | 68.86 - 70.89 |
| Regular Market Open | 69.77 |
| Regular Market Previous Close | 67.98 |
| Regular Market Price | 69.51 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 3,173,067 |
| Return On Assets | 0.14352 |
| Return On Equity | 0.75496 |
| Revenue Growth | 104.613 |
| Revenue Per Share | 7.975 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 140,032,190 |
| Shares Percent Shares Out | 0.0929 |
| Shares Short | 13,004,381 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,141,896 |
| Short Name | Arrowhead Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1296 |
| Short Ratio | 5.3 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARWR |
| Target High Price | 110.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 81.09091 |
| Target Median Price | 80.0 |
| Total Cash | 914,710,016 |
| Total Cash Per Share | 6.532 |
| Total Debt | 698,163,008 |
| Total Revenue | 1,090,980,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.6 |
| Trailing P E | 43.443752 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 45.8487 |
| Two Hundred Day Average Change | 23.6613 |
| Two Hundred Day Average Change Percent | 0.5160735 |
| Type Disp | Equity |
| Volume | 3,173,067 |
| Website | https://arrowheadpharma.com |
| Zip | 91,105 |